

FACTOR XI (HUMAN)

OTHER NAMES	Factor XI Concentrate
PRODUCT COMPOSITION	Product is a purified, sterile, lyophilized concentrate of human blood coagulation factor XI. Factor XI concentrate is cell-free and therefore is administered without regard to patient ABO or Rh type. Product is packed in quantities of 1000IU.
INFORMED CONSENT	Required
ALTERNATIVES	<p>Non-blood Product: None</p> <p>Blood Product: None</p>
DOSAGE	<ul style="list-style-type: none"> Dosage and duration of treatment will depend on the patient factor deficiency and the circumstances necessitating the treatment The manufacturer product monograph will provide specific dosage guidelines Ordered as IU (international units) and a timed frequency (e.g. Q2h) Transfusion Medicine (TM) will provide the dose requested $\pm 10\%$ depending on available vial sizes
ADMINISTRATION	<ul style="list-style-type: none"> Reconstituted and filtered by TM and supplied to unit in a syringe Product is best given immediately after preparation, MUST be within 1 hour of reconstitution Should be inspected visually for particulate matter and discoloration prior to administration Should be given IV direct push, recommended no more than 3ml per minute Flush tubing pre and post infusion with 0.9% NaCl <p>Administer the entire amount</p>
DIAGNOSTIC MONITORING	<p>Vital sign monitoring as per hospital policy for any blood, blood component and other related product. In the event of an immediate or suspected transfusion reaction, refer to hospital policy and procedures.</p> <ul style="list-style-type: none"> Allergic / Anaphylactic reactions have been noted; it is suggested to remain with patient at least 5 minutes following administration
CLINICAL INDICATIONS	Factor XI is indicated for the control and prevention of bleeding episodes in patients with either congenital Factor XI deficiency, or acquired Factor XI inhibitors.
SPECIAL CONSIDERATIONS	<ul style="list-style-type: none"> TM will need approximately 30 minutes preparation time TM needs prompt notification of changes of both dosage and/or frequency Factor XI concentrates have been associated with the development of thromboembolic complications and should be used with caution in patients with signs of fibrinolysis and DIC FACTOR XI is not approved for general use in Canada and requires special approval from the Public Health Agency of Canada (PHAC), contact TM (local 68003)
STORAGE CONDITIONS	DO NOT REFRIGERATE AFTER RECONSTITUTION
REFERENCES	Review product monograph